Modern Approaches to the Diagnosis and treatment of Clostridioides difficile (C. difficile)-associated Disease in Adults (literature Review and Expert Council Resolution)
V. T. Ivashkin,
I. V. Maev,
D. N. Andreev,
O. V. Goloshchapov,
A. A. Derinov,
O. Yu. Zolnikova,
K. V. Ivashkin,
O. Yu. Kiseleva,
A. P. Kiryukhin,
O. S. Lyashenko,
E. A. Poluektova,
A. S. Tertychnyy,
A. S. Trukhmanov,
A. I. Ulyanin,
A. A. Sheptulin,
O. S. Shifrin https://doi.org/10.22416/1382-4376-2023-33-2-19-33
Abstract
Aim: to review the modern approaches to the diagnosis and treatment of C. difficile-associated disease in adults and present the resolution of the Expert Council held on March 25, 2023 in Moscow.
General provisions. C. difficile is the most important nosocomial pathogen which spores are also commonly found in the environment. Microbiota impairment, primarily due to the use of antibacterial drugs, is a key stage in the development of C. difficile-associated disease. A search for an infection should be carried out only in patients with diarrhea, and it is advisable to use at least 2 laboratory methods. The drug of choice for first-line treatment is vancomycin. If drug treatment is ineffective or the patient has recurrent clostridial infection, fecal microbiota transplantation should be considered. The probiotic strain Saccharomyces boulardii CNCM I-745 has a direct inhibitory effect on C. difficile toxin A, promotes normalization of the intestinal microbiota composition, and decreases the inflammatory reaction in colonic mucosa colonized with a toxigenic strain of C. difficile.
Conclusions. Addition of the probiotic strain Saccharomyces boulardii CNCM I-745 to antibacterial therapy promotes both primary and secondary prevention of C. difficile-associated disease.
Keywords
intestinal microbiota,
antibiotics,
diarrhea,
C. difficile,
pseudomembranous colitis,
video colonoscopy,
fecal transplantation,
probiotics,
Saccharomyces boulardii CNCM I-745
Supporting agencies: The Expert Council was held with the organizational support of the pharmaceutical company Biocodex.
About the Authors
V. T. Ivashkin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Vladimir T. Ivashkin — Dr. Sci. (Med.), RAS Academician, Prof., Departmental Head, Department of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology, N.V. Chief of Vasilenko Clinic of Internal Disease Propaedeutics, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1
I. V. Maev
A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Igor V. Maev — Dr. Sci. (Med.), RAS Academician, Prof., Departmental Head, Department of Propaedeutics of Internal Diseases and Gastroenterology, A.I. Yevdokimov Moscow State University of Medicine and Dentistry.
127473, Moscow, Delegatskaya str., 20, bld. 1
D. N. Andreev
A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Dmitry N. Andreev — Cand. Sci. (Med.), Assoc. Prof., Department of Internal Medicine Propaedeutics and Gastroenterology, Yevdokimov Moscow State University of Medicine and Dentistry.
127473, Moscow, Delegatskaya str., 20, bld. 1
O. V. Goloshchapov
I.P. Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
Oleg V. Goloshchapov — Cand. Sci. (Med.), Research Assistant, Department of anesthesiology and resuscitation, Pavlov University, St. Petersburg, Head of ICU No. 3, R.M. Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation.
197022, Saint Petersburg, L'va Tolstogo str., 6-8
A. A. Derinov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Aleksandr A. Derinov — Cand. Sci. (Med.), Associate Professor; Department of Surgery, Institute of Clinical Medicine, Sechenov First Moscow State Medical University.
119435, Moscow, Pogodinskaya str., 1, bld. 1
O. Yu. Zolnikova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Oksana Yu. Zolnikova — Dr. Sci. (Med.), Professor; Chair of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University); Chief External Gastroenterologist of the Central Federal District of the Russian Federation.
119435, Moscow, Pogodinskaya str., 1, bld. 1
K. V. Ivashkin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Konstantin V. Ivashkin — Cand. Sci. (Med.), Associate Professor; Chair of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1
O. Yu. Kiseleva
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Olga Yu. Kiseleva — Cand. Sci. (Med.); Head of the Department of Resuscitation and Intensive Care, Vasilenko Clinic of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1
A. P. Kiryukhin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Andrey P. Kiryukhin — Cand. Sci. (Med.); Endoscopist, Department of Diagnostic and Therapeutic Endoscopy, University Clinical Hospital No 2, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1
O. S. Lyashenko
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Olga S. Lyashenko — Gastroenterologist, Department of Gastroenterology, Vasilenko Clinic of Internal Disease Propaedeutics, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1
E. A. Poluektova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Elena A. Poluektova — Dr. Sci. (Med.), Prof., Chair of Internal Disease Propaedeutics, Gastroenterology and Hepatology; Gastroenterologist, Department of Chronic Intestinal and Pancreatic Diseases, Vasilenko Clinic of Internal Disease Propaedeutics, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1
A. S. Tertychnyy
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Aleksandr S. Tertychnyy — Dr. Sci. (Med.), Professor; Strukov Department of Anatomical Pathology, Sechenov First Moscow State Medical University (Sechenov University).
119048, Moscow, Trubetskaya str., 8, bld. 2
A. S. Trukhmanov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Alexander S. Trukhmanov — Dr. Sci. (Med.), Professor; Chair of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1
A. I. Ulyanin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Anatoly I. Ulyanin — Gastroenterologist, Department of Chronic Intestinal and Pancreatic Diseases, Vasilenko Clinic of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1
A. A. Sheptulin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Arkadiy A. Sheptulin — Dr. Sci. (Med.), Professor; Chair of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology, First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1
O. S. Shifrin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Oleg S. Shifrin — Dr. Sci. (Med.), Professor; Chair of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology; Head, Department of Chronic Intestinal and Pancreatic Diseases, Vasilenko Clinic of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1
References
1. Chang L.L., Allegretti J., Skinner A.M., Dubberke E.R. Oral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent Clostridioides difficile Infection. N Engl J Med. 2023;388(7):654-6. DOI: 10.1056/NEJMcl-de2204692
2. Ivashkin V.T., Yushchuk N.D., Mayev I.V., Lapina T.L., Poluektova Ye.A., Shifrin O.S., et al. Diagnostics and treatment of Clostridium difficile-associated disease: Guidelines of the Russian gastroenterological association. Rus J Gastroenterol Hepatol Coloproctol. 2016;26(5):56— 65 (In Russ.). DOI: 10.22416/1382-4376-2016-26-5-56-65
3. Fu Y., Luo Y., Grinspan A.M. Epidemiology of community-acquired and recurrent Clostridioides difficile infection. Therap Adv Gastroenterol. 2021;14:17562848211016248. DOI: 10.1177/17562848211016248
4. Singh T., Bedi P., Bumrah K., Singh J., Rai M., Seelam S. Updates in Treatment of Recurrent Clostridium difficile Infection. J Clin Med Res. 2019;11(7):465-71. DOI: 10.14740/jocmr3854
5. Kelly C.R., Fischer M., Allegretti J.R., LaPlante K., Stewart D.B., Limketkai B.N., Stollman N.H. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2021;116(6):1124-47. DOI: 10.14309/ajg.0000000000001278. Erratum in: Am J Gastroenterol. 2022 Feb 1;117(2):358.
6. Van Hise N.W., Bryant A.M., Hennessey E.K., Crannage A.J., Khoury J.A., et al. Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents. Clin Infect Dis. 2016;63(5):651-3. DOI: 10.1093/cid/ciw401
7. Carignan A., Poulin S., Martin P., Labbe A.C., Valiquette L., Al-Bachari H., et al. Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections. Am J Gastroenterol. 2016;111(12):1834-40. DOI: 10.1038/ajg.2016.417
8. Babar S., El Kurdi B., El Iskandarani M., Haddad I., Imam Z., Alomari M., et al. Oral vancomycin prophylaxis for the prevention of Clostridium difficile infection: A systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2020;41(11):1302-9. DOI: 10.1017/ice.2020.277
9. Palleja A., Mikkelsen K.H., Forslund S.K., Kashani A., Allin K.H., Nielsen T., et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018;3(11):1255-65. DOI: 10.1038/s41564-018-0257-9
10. Schubert A.M., Sinani H., Schloss P.D. Antibiotic-Induced Alterations of the Murine Gut Microbiota and Subsequent Effects on Colonization Resistance against Clostridium difficile. mBio. 2015;6(4):e00974. DOI: 10.1128/mBio.00974-15
11. Martinez E., Taminiau B., Rodriguez C., Daube G. Gut Microbiota Composition Associated with Clostridioides difficile Colonization and Infection. Pathogens. 2022;11(7):781. DOI: 10.3390/pathogens11070781
12. Tomas M.E., Mana T.S.C., Wilson B.M., Nerandzic M.M., Joussef-Pina S., Quinones-Mateu M.E., Donskey C.J. Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice. Antimicrob Agents Chemother. 2018;62(5):e02237-17. DOI: 10.1128/AAC.02237-17
13. Lawler A.J., Lambert P.A., Worthington T. A Revised Understanding of Clostridioides difficile Spore Germination. Trends Microbiol. 2020;28(9):744-52. DOI: 10.1016/j.tim.2020.03.004
14. Crobach M.T.J., Vernon J.J, Loo V.G., Kong L.Y., Pechine S., Wilcox M.H., Kuijpera E.J. Understanding Clostridium difficile Colonization. Clin Microbiol Rev. 2018;31(2):e00021-17. DOI: 10.1128/CMR.00021-17
15. Moono P., Lim S.C., Thomas V. Riley High prevalence of toxigenic Clostridium difficile in public space lawns in Western Australia. Sci Rep. 2017;7:41196. DOI: 10.1038/srep41196
16. Xu C., Weese J.S., Flemming C., Odumeru J., Warriner K. Fate of Clostridium difficile during wastewater treatment and incidence in Southern Ontario watersheds. J Appl Microbiol. 2014;117(3):891-904. DOI: 10.1111/jam.12575
17. Knetsch C.W., Connor T.R., Mutreja A., van Dorp S.M., Sanders I.M., Browne H.P., et al. Whole genome sequencing reveals potential spread of Clostridium difficile between humans and farm animals in the Netherlands, 2002 to 2011. Euro Surveill. 2014;19(45):20954. DOI: 10.2807/1560-7917.es2014.19.45.20954
18. Knight D.R., Squire M.M., Collins D.A., Riley T.V. Genome Analysis of Clostridium difficile PCR Ribotype 014 Lineage in Australian Pigs and Humans Reveals a Diverse Genetic Repertoire and Signatures of Long-Range Interspecies Transmission. Front Microbiol. 2017;7:2138. DOI: 10.3389/fmicb.2016.02138
19. Loo V.G., Brassard P., Miller M.A. Household Transmission of Clostridium difficile to Family Members and Domestic Pets. Infect Control Hosp Epidemiol. 2016;37(11):1342-8. DOI: 10.1017/ice.2016.178
20. Kordus S.L., Thomas A.K., Lacy D.B. Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics. Nat Rev Microbiol. 2022;20(5):285—98. DOI: 10.1038/s41579-021-00660-2
21. Mullish B.H., Allegretti J.R. The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infec-tion. Therap Adv Gastroenterol. 2021;14:17562848211017725. DOI: 10.1177/17562848211017725
22. Semenyuk E.G., Poroyko V.A., Johnston P.F., Jones S.E., Knight K.L, Gerding D.N., Driks A. Analysis of Bacterial Communities during Clostridium difficile Infection in the Mouse. Infect Immun. 2015;83(11):4383—91. DOI: 10.1128/IAI.00145-15
23. Ouyang Z.R., Niu X.R., Wang W.G., Zhao J.H. The role of short-chain fatty acids in Clostridioides difficile infection: A review. Anaerobe. 2022;75:102585. DOI: 10.1016/j.anaerobe.2022.102585
24. Hernandez Del Pino R.E., Barbero A.M., Espanol L.A., Morro L.S., Pasquinelli V. The adaptive immune response to Clostridioides difficile: A tricky balance between immunoprotection and immunopathogenesis. J Leukoc Biol. 2021;109(1):195-210. DOI: 1O.1002/JLB.4VMR072O-201R
25. Khurana S., Kahl A., Yu K., DuPont A.W. Recent advances in the treatment of Clostridioides difficile infection: the ever-changing guidelines. Fac Rev. 2020;9:13. DOI: 10.12703/b/9-13
26. Kukla M., Adrych K., Dobrowolska A., Mach T., Regula J., Rydzewska G. Guidelines for Clostridium difficile infection in adults. Gastroenterology Rev. 2020;15(1):1-21. DOI: 10.5114/pg.2020.93629
27. Czepiel J., Drozdz M., Pituch H., Kuijper E.J., Perucki W., Mielimonka A., et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019;38(7):1211-21. DOI: 10.1007/s10096-019-03539-6
28. McDonald L.C., Gerding D.N., Johnson S., Bakken J.S., Carroll K.C,, Coffin S.E., et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-48. DOI: 10.1093/cid/ciy149
29. Baker S.J., Chu D.I. Physical, Laboratory, Radiographic, and Endoscopic Workup for Clostridium difficile Colitis. Clin Colon Rectal Surg. 2020;33(2):82-6. DOI: 10.1055/s-0039-3400474
30. Tagliaferri A.R., Murray K., Michael P. A Case of Pseudomembranous Colitis of Unknown Etiology. Cureus. 2022;14(2):e21914. DOI: 10.7759/cureus.21914
31. Chandrasekaran R., Lacy D.B. The role of toxins in Clostridium difficile infection. FEMS Microbiol Rev. 2017;41(6):723-50. DOI: 10.1093/femsre/fux048
32. Abdul J.S., Sundaramurthi S., Elamurugan T.P., Goneppanavar M., Nelamangala R.V.P. An Unusual Presentation of Pseudomembranous Colitis. Cureus. 2019;11(4):e4570. DOI: 10.7759/cureus.4570
33. Talbot I., Price A., Salto-Tellez M. Biopsy Pathology in Colorectal Disease. 2nd ed. London, CRS Press; 2006. DOI: 10.1201/b13363
34. Olofinlade O., Chiang C. Cytomegalovirus infection as a cause of pseudomembrane colitis: a report of four cases. J Clin Gastroenterol. 2001;32(1):82-4. DOI: 10.1097/00004836-200101000-00019
35. Аруин Л.И., Капуллер Л.Л., Исаков В.А. Морфологическая диагностика болезней желудка и кишечника. М.: Триада-Х, 1998.
36. Cerilli L.A., Greenson J.K. The differential diagnosis of colitis in endoscopic biopsy specimens: a review article. Arch Pathol Lab Med. 2012;136(8):854-64. DOI: 10.5858/arpa.2012-0205-RA
37. Kwon J.H., Reske K.A., Hink T., Burnham C.A.D., Dubberke E.R. Evaluation of Correlation between Pretest Probability for Clostridium difficile Infection and Clostridium difficile Enzyme Immunoassay Results. J Clin Microbiol. 2017;55(2):596-605. DOI: 10.1128/JCM.02126-16
38. Johnson S., Lavergne V., Skinner A.M., Gonzales-Luna A.J., Garey K.W., Kelly C.P., Wilcox M.H. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021;73(5):e1029-44. DOI: 10.1093/cid/ciab549
39. Guh A.Y., Kutty P.K. Clostridioides difficile Infection. Ann Intern Med. 2018;169(7):ITC49-64. DOI: 10.7326/AITC201810020
40. Nelson R.L., Suda K.J., Evans C.T. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev. 2017;3(3):CD004610. DOI: 10.1002/14651858.CD004610.pub5
41. Johnson S., Louie T.G., Gerding D.N., Cornely O.A., Chasan-Taber S., Fitts D., Gelone S.P., Broom C., Davidson D.M. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59(3):345-54. DOI: 10.1093/cid/ciu313
42. Baunwall S.M.D., Lee M.M, Eriksen M.K., Mullish B.H., Marchesi J.R., Dahlerup J.F., Hvas C.L. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis. EClinicalMedicine. 2020;29-30:100642. DOI: 10.1016/j.eclinm.2020.100642
43. Rapoport E.A., Baig M., Puli S.R. Adverse events in fecal microbiota transplantation: a systematic review and meta-analysis. Ann Gastroenterol. 2022;35(2):150-63. DOI: 10.20524/aog.2022.0695
44. McFarland L.V., Evans C.T., Goldstein E.J.C. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2018;5:124. DOI: 10.3389/fmed.2018.00124
45. Raseen T., Devvrat Y., Muhammad Waqas T., Kanika S., Darrell P., Sahil K. S136 Efficacy of Saccharomyces boulardii for Prevention of Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2021;116(1):S59-60. DOI: 10.14309/01.ajg.0000773016.43460.eb
46. Duan J., Meng X., Liu S., Zhou P., Zeng C., Fu C., et al. Gut Microbiota Composition Associated With Clostridium difficile-Positive Diarrhea and C. difficile Type in ICU Patients. Front Cell Infect Microbiol. 2020;10:190. DOI: 10.3389/fcimb.2020.00190
47. Berkell M., Mysara M., Xavier B.B., Werkhoven C.H., Monsieurs P., Lammens C., et al. Microbiota-based markers predictive of development of Clostridioides difficile infection. Nat Commun. 2021;12(1):2241. DOI: 10.1038/s41467-021-22302-0
48. Goldenberg J.Z., Yap C., Lytvyn L., Lo C.K., Beardsley J., Mertz D., Johnston B.C. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Sys Rev. 2017;12(12):CD006095. DOI: 10.1002/14651858.CD006095.pub4
49. Lau C.S.M., Chamberlain R.S. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016;9:27-37. DOI: 10.2147/IJGM.S98280
50. Shen N.T., Maw A., Tmanova L.L., Pino A., Ancy K., Crawford C.V., et al. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. Gastroenterology. 2017;152(8):1889-900.e9. DOI: 10.1053/j.gastro.2017.02.003
51. Madoff S.E., Urquiaga M., Alonso C.D., Kelly C.P. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials. Anaerobe. 2020;61:102098. DOI: 10.1016/j.anaerobe.2019.102098
52. Kazmierczak-Siedlecka K., Ruszkowski J., Fic M., Folwarski M., Makarewicz W. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases. Curr Microbiol. 2020 Sep;77(9):1987-96. DOI: 10.1007/s00284-020-02053-9
53. Valdes-Varela L., Gueimonde M., Ruas-Madiedo P. Probiotics for Prevention and Treatment of Clostridium difficile Infection. Adv Exp Med Biol. 2018;1050:161-76. DOI: 10.1007/978-3-319-72799-8_10
54. Gaisawat M.B., MacPherson C.W., Tremblay J., Piano A., Iskandar M.M., Tompkins T.A., Kubow S. Probiotic Supplementation in a Clostridium difficile-Infected Gastrointestinal Model Is Associated with Restoring Metabolic Function of Microbiota. Microorganisms. 2020;8(1):60. DOI: 10.3390/microorganisms8010060
55. Lacotte P.A., Simons A., Bouttier S., Malet-Villemagne J., Nicolas V., Janoir C. Inhibition of In Vitro Clostridioides difficile Biofilm Formation by the Probiotic Yeast Saccharomyces boulardii CNCM I-745 through Modification of the Extracellular Matrix Composition. Microorganisms. 2022;10(6):1082. DOI: 10.3390/microorganisms10061082
56. Kelly C.P., Chong-Nguyen C., Palmieri L.J., Pallav K., Dowd S.E., Humbert L., et al. Saccharomyces boulardii CNCM I-745 modulates the fecal bile acids metabolism during antimicrobial therapy in healthy volunteers. Front Microbiol. 2019;10:336. DOI: 10.3389/fmicb.2019.00336
57. Koon H.W., Su B., Xu C., Mussatto C.C., Tran D.H., Lee E.C., et al. Probiotic Saccharomyces boulardii CNCM I-745 prevents outbreak-associated Clostridium difficile-associated cecal inflammation in hamsters. Am J Physiol Gastrointest Liver Physiol. 2016;311(4):G610-23. DOI: 10.1152/ajpgi.00150.2016
58. Ivashkin V.T., Maev I.V., Abdulganieva D.I., Alekseenko S.A., Gorelov A.V., Zakharova I.N., et al. Practical Recommendations of Scientific Society for the Study of Human Microbiome and the Russian Gastroenterological Association on Use of Probiotics, Prebiotics, Synbiotics and Functional Foods in Treatment and Prevention of Gastroenterological Diseases in Children and Adults. Rus J Gastroenterol Hepatol Coloproctol. 2021;31(2):65-91 (In Russ.). DOI: 10.22416/1382-4376-2021-31-2-65-91
59. Cammarota G., Ianiro G., Tilg H., The European FMT Working Group, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66:569-80. DOI: 10.1136/gutjnl-2016-313017
60. Goloshchapov O.V., Chukhlovin A.B., Bakin E.A., Stanevich O.V., Klementeva R.V., Shcherbakov A.A., et al. Fecal microbiota transplantation for graft-versus-host disease in children and adults: methods, clinical effects, safety. Terapevticheskiy arkhiv. 2020;92(7):43-54 (In Russ.). DOI: 10.26442/00403660.2020.07.000773
61. Hvas C.L., J0rgensen S.M.D., J0rgensen S.P., Storgaard M., Lemming L., Hansen M.M., et al. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection. Gastroenterology. 2019;156(5):1324-32.e3. DOI: 10.1053/j.gastro.2018.12.019
62. Wang J.W., Kuo C.H., Kuo F.C., Wang Y.K., Hsu W.H., Yu F.J., et al. Fecal microbiota transplantation: Review and update. J Formos Med Assoc. 2019;118 (Suppl 1):S23-31. DOI: 10.1016/j.jfma.2018.08.011
63. Panchal P., Budree S., Scheeler A., Medina G., Seng M., Wong W.F., et al. Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future. Curr Gastroenterol Rep. 2018;20(4):14. DOI: 10.1007/s11894-018-0619-8
64. Tkach S., Dorofeyev A., Kuzenko I., Boyko N., Falalyeyeva T., Boccuto L., et al. Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation. Medicina (Kaunas). 2022;58(1):84. DOI: 10.3390/medicina58010084
65. Marcella C., Cui B., Kelly C.R., Ianiro G., Cammarota G., Zhang F. Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020. Aliment Pharmacol Ther. 2021;53(1):33-42. DOI: 10.1111/apt.16148
Supplementary files
Review
For citations:
Ivashkin V.T., Maev I.V., Andreev D.N., Goloshchapov O.V., Derinov A.A., Zolnikova O.Yu., Ivashkin K.V., Kiseleva O.Yu., Kiryukhin A.P., Lyashenko O.S., Poluektova E.A., Tertychnyy A.S., Trukhmanov A.S., Ulyanin A.I., Sheptulin A.A., Shifrin O.S. Modern Approaches to the Diagnosis and treatment of Clostridioides difficile (C. difficile)-associated Disease in Adults (literature Review and Expert Council Resolution). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(2):19-33. https://doi.org/10.22416/1382-4376-2023-33-2-19-33
Views:
2755
Email this article 
